Fujian Aonong Biological Technology Group Incorporation 과거 수익 실적

과거 기준 확인 0/6

Fujian Aonong Biological Technology Group Incorporation의 수입은 연평균 -59.4%의 비율로 감소해 온 반면, Food 산업은 수입이 연평균 2.5%의 비율로 증가했습니다. 매출은 연평균 16.9%의 비율로 증가해 왔습니다.

주요 정보

-59.4%

수익 성장률

-55.5%

EPS 성장률

Food 산업 성장	7.2%
매출 성장률	16.9%
자기자본 수익률	n/a
순이익	-28.4%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Shares Not Telling The Full Story

Aug 22

Market Cool On Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Revenues Pushing Shares 30% Lower

May 02

수익 및 비용 분석

Fujian Aonong Biological Technology Group Incorporation 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SHSE:603363 수익, 비용 및 수입 (CNY Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	11,206	-3,180	1,169	76
30 Jun 24	14,047	-3,382	1,168	97
31 Mar 24	17,048	-3,763	1,147	116
31 Dec 23	19,458	-3,651	1,117	149
30 Sep 23	21,387	-1,756	1,076	162
30 Jun 23	22,862	-1,171	1,105	172
31 Mar 23	22,276	-866	1,100	176
31 Dec 22	21,613	-1,038	1,098	162
30 Sep 22	20,119	-1,590	1,136	148
30 Jun 22	18,636	-2,034	1,028	134
31 Mar 22	18,299	-2,034	1,016	126
31 Dec 21	18,038	-1,520	990	114
30 Sep 21	17,504	-432	928	98
30 Jun 21	15,649	72	907	88
31 Mar 21	13,663	584	835	74
31 Dec 20	11,517	573	740	65
30 Sep 20	8,860	491	620	61
30 Jun 20	7,165	346	529	58
31 Mar 20	6,197	163	485	63
31 Dec 19	5,788	29	474	73
30 Sep 19	5,794	39	505	86
30 Jun 19	5,736	35	526	102
31 Mar 19	5,746	33	547	107
31 Dec 18	5,762	30	571	110
30 Sep 18	5,675	49	609	107
30 Jun 18	5,376	61	566	159
31 Mar 18	5,137	99	602	132
31 Dec 17	4,903	108	631	107
30 Sep 17	4,960	119	633	81
31 Dec 16	4,978	91	722	0
31 Dec 15	4,013	34	676	0
31 Dec 14	4,184	43	626	0

양질의 수익: 603363 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 603363 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 603363 은(는) 수익성이 없으며 지난 5년 동안 연간 59.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 603363 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 603363 은(는) 수익성이 없어 지난 해 수익 성장을 Food 업계( -5.8% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 603363 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Fujian Aonong Biological Technology Group Incorporation 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.56 loss in 3Q 2023)

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.71 loss in 2Q 2023)

Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2024 Results on Aug 31, 2024

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2023 Results on Apr 30, 2024

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.56 loss in 3Q 2023)

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.71 loss in 2Q 2023)

Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Shares Not Telling The Full Story

Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2024 Results on Aug 31, 2024

Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024

Market Cool On Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Revenues Pushing Shares 30% Lower

Less than half of directors are independent

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.56 loss per share (vs CN¥0.12 profit in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.71 loss per share (vs CN¥0.42 loss in 2Q 2022)

First quarter 2023 earnings released: CN¥0.21 loss per share (vs CN¥0.54 loss in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.50 loss in 3Q 2021)

Now 20% undervalued after recent price drop

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.50 loss per share (vs CN¥0.25 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.54 loss per share (vs CN¥0.33 profit in 2Q 2020)

Price target increased to CN¥29.16

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.27 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.95 (vs CN¥0.054 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥15.51

Investor sentiment improved over the past week

New 90-day low: CN¥12.37

New 90-day low: CN¥13.15

New 90-day low: CN¥13.54

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥13.63

Liu Xueke, Su Guoyang, Wu Boyuan, and Liu Lianlong agreed to acquire 21% stake in Xiamen Aomu Trade Co., Ltd from Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) for CNY 0.

New 90-day low - CN¥20.10

Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) completed the acquisition of the remaining 70% stake in Xiamen Yinxiang Meat Industry Co., Ltd. from Xiamen Yinxiang Group Co., Ltd.

New 90-day high - CN¥26.31

Earnings released

Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2020 Results on Aug 20, 2020

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기